Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Gastrointestinal Cancers: Molecular Mechanisms and Therapies
share announcement

Gastrointestinal Cancers: Molecular Mechanisms and Therapies

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (15 June 2022) | Viewed by 5838

Special Issue Editors

Dr. Seok-Jun Kim

E-Mail Website
Guest Editor
Department of Biomedical Science, Chosun University, Gwangju 61452, Republic of Korea
Interests: gastric cancer; signal transduction (Wnt and Notch signaling); inflammation; drug repositioning; aptamers
Special Issues, Collections and Topics in MDPI journals
Dr. Valentina Calò

E-Mail Website
Guest Editor
Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy
Interests: oncology; cancer research; molecular biology; genetics; BRCA 1\2; genetic diseases; gene signatures
Dr. Marta Castiglia

E-Mail
Co-Guest Editor
Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy
Interests: human genetics; molecular genetics; biomarker discovery; translational research; liquid biopsy (circulating tumor DNA and exosomes)
Dr. Nadia Barraco

E-Mail
Co-Guest Editor
Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy
Interests: molecular biomarker; colon cancer; gastric cancer; pancreatic cancer; genetics; therapeutic targets; precision medicine; tumor microenvironment

Special Issue Information

Dear Colleagues,

This Special Issue on “Gastrointestinal Cancers: Molecular Mechanisms and Therapies” will mainly focus on analyzing present and future approaches for the treatment of gastrointestinal cancer patients, with a glimpse of novel perspectives and future challenges in clinical practice. Gastrointestinal cancers are one of the most common worldwide cause of cancer-related death. In the last decade, significant improvements have been made in the prognosis of patients with gastrointestinal cancers deriving from the development of modern tailored therapies, which include cytotoxic drugs, targeted therapies, and immunotherapy. Recently, emerging and novel biomarkers have been identified and validated with a huge impact on patients’ outcomes and improving the treatment landscape. Despite these advances, gastrointestinal cancers still represent a major public health problem worldwide; hence, it is mandatory to develop novel therapeutic approaches for patients affected by those cancers. We cordially invite experts in the field to submit original research or review articles pertaining to this important and fast-progressing field of biomedicine.

Dr. Seok-Jun Kim
Dr. Valentina Calò
Guest Editors
Dr. Marta Castiglia
Dr. Nadia Barraco
Co-Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • molecular biomarker
  • colon cancer
  • gastric cancer
  • pancreatic cancer
  • genetics
  • therapeutic targets
  • precision medicine
  • tumor microenvironment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 3560 KiB  
Article
CD44v6 High Membranous Expression Is a Predictive Marker of Therapy Response in Gastric Cancer Patients
by Gabriela M Almeida, Carla Pereira, Ji-Hyeon Park, Carolina Lemos, Sofia Campelos, Irene Gullo, Diana Martins, Gilza Gonçalves, Dina Leitão, João Luís Neto, Ana André, Clara Borges, Daniela Almeida, Hyuk-Joon Lee, Seong-Ho Kong, Woo Ho Kim, Fátima Carneiro, Raquel Almeida, Han-Kwang Yang and Carla Oliveira
Biomedicines 2021, 9(9), 1249; https://doi.org/10.3390/biomedicines9091249 - 18 Sep 2021
Cited by 4 | Viewed by 2473
Abstract
In gastric cancer (GC), biomarkers that define prognosis and predict treatment response remain scarce. We hypothesized that the extent of CD44v6 membranous tumor expression could predict prognosis and therapy response in GC patients. Two GC surgical cohorts, from Portugal and South Korea ( [...] Read more.
In gastric cancer (GC), biomarkers that define prognosis and predict treatment response remain scarce. We hypothesized that the extent of CD44v6 membranous tumor expression could predict prognosis and therapy response in GC patients. Two GC surgical cohorts, from Portugal and South Korea (n = 964), were characterized for the extension of CD44v6 membranous immuno-expression, clinicopathological features, patient survival, and therapy response. The value of CD44v6 expression in predicting response to treatment and its impact on prognosis was determined. High CD44v6 expression was associated with invasive features (perineural invasion and depth of invasion) in both cohorts and with worse survival in the Portuguese GC cohort (HR 1.461; 95% confidence interval 1.002–2.131). Patients with high CD44v6 tumor expression benefited from conventional chemotherapy in addition to surgery (p < 0.05), particularly those with heterogeneous CD44v6-positive and -negative populations (CD44v6_3+) (p < 0.007 and p < 0.009). Our study is the first to identify CD44v6 high membranous expression as a potential predictive marker of response to conventional treatment, but it does not clarify CD44v6 prognostic value in GC. Importantly, our data support selection of GC patients with high CD44v6-expressing tumors for conventional chemotherapy in addition to surgery. These findings will allow better stratification of GC patients for treatment, potentially improving their overall survival. Full article
(This article belongs to the Special Issue Gastrointestinal Cancers: Molecular Mechanisms and Therapies)
►▼ Show Figures

Figure 1

Review

Jump to: Research

11 pages, 620 KiB  
Review
Heat Shock Factor 1 as a Prognostic and Diagnostic Biomarker of Gastric Cancer
by Woong Kim and Seok-Jun Kim
Biomedicines 2021, 9(6), 586; https://doi.org/10.3390/biomedicines9060586 - 21 May 2021
Cited by 5 | Viewed by 2368
Abstract
Identification of effective prognostic and diagnostic biomarkers is needed to improve the diagnosis and treatment of gastric cancer. Early detection of gastric cancer through diagnostic markers can help establish effective treatments. Heat shock factor 1 (HSF1), presented in this review, is known to [...] Read more.
Identification of effective prognostic and diagnostic biomarkers is needed to improve the diagnosis and treatment of gastric cancer. Early detection of gastric cancer through diagnostic markers can help establish effective treatments. Heat shock factor 1 (HSF1), presented in this review, is known to be regulated by a broad range of transcription factors, including those characterized in various malignant tumors, including gastric cancer. Particularly, it has been demonstrated that HSF1 regulation in various cancers is correlated with different processes, such as cell death, proliferation, and metastasis. Due to the effect of HSF1 on the initiation, development, and progression of various tumors, it is considered as an important gene for understanding and treating tumors. Additionally, HSF1 exhibits high expression in various cancers, and its high expression adversely affects the prognosis of various cancer patients, thereby suggesting that it can be used as a novel, predictive, prognostic, and diagnostic biomarker for gastric cancer. In this review, we discuss the literature accumulated in recent years, which suggests that there is a correlation between the expression of HSF1 and prognosis of gastric cancer patients through public data. Consequently, this evidence also indicates that HSF1 can be established as a powerful biomarker for the prognosis and diagnosis of gastric cancer. Full article
(This article belongs to the Special Issue Gastrointestinal Cancers: Molecular Mechanisms and Therapies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop